After the spin-off of Alcon was approved by Novartis shareholders...

After the spin-off of Alcon was approved by Novartis shareholders with 99.8 percent of the votes at the general annual meeting on Feb. 28, the pharmaceutical giant announced that it had received all necessary authorizations to move ahead. The transaction is now expected to be completed on April 9, 2019, ...

To continue reading this article subscribe now


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Our executive edition of Eyewear Intelligence (Regular PDF format or E-Format) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Unlimited access to - all insight, analysis and statistics available online
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation
  • Breaking news

Already an Eyewear Intelligence subscriber? Sign in here.